Hot Features
Registrieren Sie sich für Echtzeit-Benachrichtigungen, benutzerdefinierte Portfolios und Marktbewegungen.
Vanda Pharmaceuticals Inc is a biopharmaceutical company engaged in the development and commercialization of therapies to address high unmet medical needs and improves the lives of patients. Its commercial portfolio comprises two products, HETLIOZ for the treatment of Non-24-Hour Sleep-Wake Disorder... Vanda Pharmaceuticals Inc is a biopharmaceutical company engaged in the development and commercialization of therapies to address high unmet medical needs and improves the lives of patients. Its commercial portfolio comprises two products, HETLIOZ for the treatment of Non-24-Hour Sleep-Wake Disorder (Non-24) and nighttime sleep disturbances in Smith-Magenis Syndrome (SMS) and Fanapt for the treatment of schizophrenia. Its other products include Tradipitant (VLY-686), VTR-297, and VQW-765. Mehr anzeigen
Vanda Pharmaceuticals Announces Orphan Drug Designation Granted for VGT-1849A, a Novel and Selective Antisense Oligonucleotide Candidate for the Treatment of Polycythemia Vera PR...
Vanda Pharmaceuticals Announces Participation at November 2024 Investor Conferences PR Newswire WASHINGTON, Nov. 12, 2024 WASHINGTON, Nov. 12, 2024 /PRNewswire/ -- Vanda Pharmaceuticals Inc...
Vanda Pharmaceuticals Reports Third Quarter 2024 Financial Results PR Newswire WASHINGTON, Nov. 6, 2024 Revenues for Q3 2024 were $47.7 million, an increase of 23% compared to Q3 2023Financial...
Vanda Pharmaceuticals to Announce Third Quarter 2024 Financial Results on November 6, 2024 PR Newswire WASHINGTON, Oct. 30, 2024 Conference Call and Webcast to Follow WASHINGTON, Oct. 30, 2024...
Vanda Pharmaceuticals Confirms Receipt of Economically Identical Unsolicited, Non-Binding Proposal from Cycle Group Holdings Ltd. PR Newswire WASHINGTON, Oct. 14, 2024 Board Has Determined That...
| Zeitraum † | Änderung | Änderung % | Handelsbeginn | Hoch | Niedrig | Durchsch. Volumen | VWAP | |
|---|---|---|---|---|---|---|---|---|
| 1 | 0 | 0 | 4.79 | 4.9 | 4.7105 | 423911 | 4.79476536 | CS |
| 4 | -0.03 | -0.622406639004 | 4.82 | 4.95 | 4.45 | 683991 | 4.69900661 | CS |
| 12 | 0.37 | 8.37104072398 | 4.42 | 5.545 | 4.35 | 691337 | 4.85962675 | CS |
| 26 | -0.79 | -14.1577060932 | 5.58 | 6.365 | 4.35 | 635205 | 5.10320889 | CS |
| 52 | 0.59 | 14.0476190476 | 4.2 | 6.75 | 3.46 | 1205665 | 4.95301083 | CS |
| 156 | -10.98 | -69.6258719087 | 15.77 | 16.925 | 3.295 | 843584 | 6.25580411 | CS |
| 260 | -11.81 | -71.1445783133 | 16.6 | 21.8627 | 3.295 | 720123 | 8.59060885 | CS |
| Keine Diskussionen Gefunden. |
| Neuen Thread Erstellen |
Die zuletzt besuchten Aktien werden in diesem Feld angezeigt, so dass Sie leicht zu den Aktien zurückkehren können, die Sie zuvor angesehen haben.
Support: +44 (0) 203 8794 460 | support@advfn.de
Durch das Benutzen des ADVFN Angebotes akzeptieren Sie folgende Allgemeine Geschäftsbedingungen
Premium
